Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 179 clinical trials
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

This is a prospective, open label, single-arm, multicenter, non-interventional study of dabrafenib in combination with trametinib as adjuvant treatment for Chinese patients with stage III BRAF

immunomodulators
braf v600 mutation
BRAF
dabrafenib
immunologic adjuvant
  • 0 views
  • 08 Mar, 2022
  • 7 locations
A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients (TavieSkin)

Background The purpose of this study is to describe the profile of patients with BRAF-mutated melanoma treated with BRAF/MEK inhibitors combination and using the Tavie Skin application

  • 0 views
  • 19 Jun, 2022
  • 1 location
Role of Circulating Tumour DNA Testing in Assessing for Alterations of Primary Anti-EGFR Resistance in RAS/RAF Wild-type Metastatic Colorectal Cancer Patients

The study aims to explore the clinical utility of circulating tumour DNA (ctDNA) in assessing for alterations of anti-epidermal growth factor receptor (EGFR) primary resistance in RAS and BRAF

  • 0 views
  • 10 Oct, 2021
  • 1 location
Study of CT and MR in the Lung Cancer

), ROS1(c-ros oncogene 1 receptor,ROS1), BRAF (V-raf murine sarcoma viral oncogene homolog B1, BRAF)and so on have clearly targeted drugs, which bring survival benefits to patients. However, about half

lung cancer
EGFR
BRAF
ct scan
epidermal growth factor receptor
  • 0 views
  • 03 Mar, 2022
  • 1 location
GIST: Assessment of Tumor Mutations and TKI Plasma Exposure

Gastrointestinal stromal tumors (GISTs) belong to the sarcoma group and are characterized by oncogenic mutations in the c-KIT, PDGFRA, BRAF and NF-1 genes that drive tumor growth. Since tyrosine

  • 1 views
  • 29 May, 2022
  • 1 location
Rare Subtypes of Gastrointestinal Cancers

A single-arm prospective observational translational study of biomarkers in patients receiving targeted treatment for rare subtypes of cancer of the Gastrointestinal Tract.

cancer
BRAF
  • 0 views
  • 22 Mar, 2022
  • 1 location
Tracing Dissemination of Melanoma Cells in Healthy Tissues (DISSEMELA)

The objective of this project is to evaluate the presence of melanoma quiescent or initiating clonal cells in peritumoral healthy tissue displaying the same molecular signature than those of the tumor/metastasis and to correlate this presence to the prognostic value.

metastasis
BRAF
NRAS
KIT
  • 10 views
  • 27 Feb, 2022
  • 1 location
Circulating Tumor DNA as Marker for Response to Antineoplastic Treatment of Metastatic Cancer (FLUIDO)

Early monitoring of antineoplastic treatment benefit is a central medical need. Radiologic assessment for documentation of response is done after several months of treatment usually. This implies that patients not responding are exposed to unnecessary toxicity. According to several reports showing the correlation of the amount of circulating tumour DNA …

  • 0 views
  • 18 Mar, 2021
  • 1 location
Liquid Biopsy for ctDNA in Peritoneal Lavage and Blood in Pancreatic Cancer (LIPAC)

Pancreatic cancer (PC) is a deadly disease and surgical resection of the tumor is the only hope of cure. Approximately 20-25% of the PC patients are candidates for intended curative resection, but despite microscopically radical resection the majority of patients will have recurrent disease within 2 years. This indicates that …

cancer chemotherapy
pancreatic resection
adenocarcinoma
pdac
tumor cells
  • 0 views
  • 16 Jun, 2022
  • 1 location